title: A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of docetaxel-cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Chemotherapy-naïve patients with histologically confirmed TNM stage III or IV NSCLC were recruited from 12 Asian trial centers. Patients received docetaxel (75 mg/m2) and cisplatin (75 mg/m2) every 3 weeks for 6 cycles.
  
  
  RESULTS
  130 of 146 patients were evaluable for efficacy (60% stage IV). Three complete and 58 partial responses were observed (overall response rate: 46.9%; 95% CI: 38.3-55.5%). Median time to progression was 6.9 months and median survival was 14.0 months; 1-year survival was 59.5%. Grade 3/4 neutropenia, thrombocytopenia and anemia occurred in 69.2%, 6.2% and 18.5% of patients, respectively. Grade 3/4 vomiting was observed in 13.7% and grade 3/4 neurosensory effects were observed in 2.7% of patients. There was one case of treatment-related death due to sepsis.
  
  
  CONCLUSIONS
  Docetaxel-cisplatin is an effective and well-tolerated treatment in Asian patients with NSCLC.
authors.affiliation: Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong, China.
authors.forename: James C M
authors.initials: JC
authors.lastname: Ho
authors.forename: E H
authors.initials: EH
authors.lastname: Tan
authors.forename: S S
authors.initials: SS
authors.lastname: Leong
authors.forename: C H
authors.initials: CH
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Sun
authors.forename: R
authors.initials: R
authors.lastname: Li
authors.forename: M I A
authors.initials: MI
authors.lastname: Wahid
authors.forename: A
authors.initials: A
authors.lastname: Jusuf
authors.forename: M
authors.initials: M
authors.lastname: Liao
authors.forename: Z
authors.initials: Z
authors.lastname: Guan
authors.forename: P
authors.initials: P
authors.lastname: Handoyo
authors.forename: J S
authors.initials: JS
authors.lastname: Huang
authors.forename: V
authors.initials: V
authors.lastname: Chan
authors.forename: G
authors.initials: G
authors.lastname: Luna
authors.forename: K W T
authors.initials: KW
authors.lastname: Tsang
authors.forename: W K
authors.initials: WK
authors.lastname: Lam
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001208:Asia; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D015996:Survival Rate; D043823:Taxoids
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel; D002945:Cisplatin